To The Moon
Home
News
TigerAI
Log In
Sign Up
optoons65
+Follow
Posts · 15
Posts · 15
Following · 0
Following · 0
Followers · 0
Followers · 0
optoons65
optoons65
·
2021-06-18
Wow
BRIEF-Biogen Reports 10.7% Passive Stake In Sage Therapeutics
Jan 11 (Reuters) - Biogen Inc : * BIOGEN INC REPORTS 10.7% PASSIVE STAKE IN SAGE THERAPEUTICS IN
BRIEF-Biogen Reports 10.7% Passive Stake In Sage Therapeutics
看
1.74K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-17
Latest
BRIEF-UP FinTech Announces Pricing Of Follow-On Public Offering Of ADS
June 9 (Reuters) -* UP FINTECH ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF AMERICAN DEPOSITARY
BRIEF-UP FinTech Announces Pricing Of Follow-On Public Offering Of ADS
看
2.21K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-17
Oh
Novavax's COVID-19 vaccine to be made in India soon - govt official
BENGALURU, June 15 (Reuters) - The Serum Institute of India is preparing to produce Novavax's COV
Novavax's COVID-19 vaccine to be made in India soon - govt official
看
2.13K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-17
Buy
Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner
Novavax Inc COVID-19 vaccine, marketed as "Covovax," could see a launch in India as early as Septemb
Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner
看
1.73K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-16
Wow
Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner
Novavax Inc COVID-19 vaccine, marketed as "Covovax," could see a launch in India as early as Septemb
Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner
看
1.89K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-16
Good
Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner
Novavax Inc COVID-19 vaccine, marketed as "Covovax," could see a launch in India as early as Septemb
Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner
看
1.80K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-16
Latest
The Fed Should Talk About Tapering. Here’s What Could Happen to the Stock Market.
Investors expect the Federal Reserve to remain supportive of the economy and financial markets. But
The Fed Should Talk About Tapering. Here’s What Could Happen to the Stock Market.
看
2.33K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-16
Latest
Sorry, this post has been deleted
看
2.02K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-15
Latest
Sorry, this post has been deleted
看
1.57K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
optoons65
optoons65
·
2021-06-14
Nice
EV stocks rose in morning trading, as sales strong
EV stocks rose in morning trading, as sales strong. Li surged 8%. Li Auto reported May deliveries of
EV stocks rose in morning trading, as sales strong
看
2.37K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3573863031138354","uuid":"3573863031138354","gmtCreate":1610771413744,"gmtModify":1759141308722,"name":"optoons65","pinyin":"optoons65","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":7,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.46%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":166254749,"gmtCreate":1624014143781,"gmtModify":1703826561560,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166254749","repostId":"2102911122","repostType":2,"repost":{"id":"2102911122","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1610406113,"share":"https://ttm.financial/m/news/2102911122?lang=en_US&edition=fundamental","pubTime":"2021-01-12 07:01","market":"us","language":"en","title":"BRIEF-Biogen Reports 10.7% Passive Stake In Sage Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2102911122","media":"Reuters","summary":"Jan 11 (Reuters) - Biogen Inc : * BIOGEN INC REPORTS 10.7% PASSIVE STAKE IN SAGE THERAPEUTICS IN","content":"<html><body><p>Jan 11 (Reuters) - Biogen Inc :</p><p> * BIOGEN INC REPORTS 10.7% PASSIVE STAKE IN SAGE THERAPEUTICS INC AS OF DEC 31, 2020 - SEC FILING</p><p>Source text: () Further company coverage: </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Biogen Reports 10.7% Passive Stake In Sage Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Biogen Reports 10.7% Passive Stake In Sage Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-01-12 07:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 11 (Reuters) - Biogen Inc :</p><p> * BIOGEN INC REPORTS 10.7% PASSIVE STAKE IN SAGE THERAPEUTICS INC AS OF DEC 31, 2020 - SEC FILING</p><p>Source text: () Further company coverage: </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","SAGE":"Sage Therapeutics"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2102911122","content_text":"Jan 11 (Reuters) - Biogen Inc : * BIOGEN INC REPORTS 10.7% PASSIVE STAKE IN SAGE THERAPEUTICS INC AS OF DEC 31, 2020 - SEC FILINGSource text: () Further company coverage: ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"SAGE":1,"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":1743,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163418956,"gmtCreate":1623891109375,"gmtModify":1703822594178,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Latest ","listText":"Latest ","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163418956","repostId":"2142297472","repostType":2,"repost":{"id":"2142297472","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623225816,"share":"https://ttm.financial/m/news/2142297472?lang=en_US&edition=fundamental","pubTime":"2021-06-09 16:03","market":"sh","language":"en","title":"BRIEF-UP FinTech Announces Pricing Of Follow-On Public Offering Of ADS","url":"https://stock-news.laohu8.com/highlight/detail?id=2142297472","media":"Reuters","summary":"June 9 (Reuters) -* UP FINTECH ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF AMERICAN DEPOSITARY","content":"<p>June 9 (Reuters) -</p><p>* UP FINTECH ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES</p><p>* UP FINTECH HOLDING SAYS PRICING OF A PUBLIC OFFERING OF 6.5 MILLION ADS AT A PUBLIC OFFERING PRICE OF US$24.50 PER ADS</p><p>Source text for Eikon: Further company coverage:</p><p>((Reuters.Briefs@thomsonreuters.com;))</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-UP FinTech Announces Pricing Of Follow-On Public Offering Of ADS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-UP FinTech Announces Pricing Of Follow-On Public Offering Of ADS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-09 16:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 9 (Reuters) -</p><p>* UP FINTECH ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES</p><p>* UP FINTECH HOLDING SAYS PRICING OF A PUBLIC OFFERING OF 6.5 MILLION ADS AT A PUBLIC OFFERING PRICE OF US$24.50 PER ADS</p><p>Source text for Eikon: Further company coverage:</p><p>((Reuters.Briefs@thomsonreuters.com;))</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TIGR":"老虎证券"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142297472","content_text":"June 9 (Reuters) -* UP FINTECH ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES* UP FINTECH HOLDING SAYS PRICING OF A PUBLIC OFFERING OF 6.5 MILLION ADS AT A PUBLIC OFFERING PRICE OF US$24.50 PER ADSSource text for Eikon: Further company coverage:((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"TIGR":0.9}},"isVote":1,"tweetType":1,"viewCount":2214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163393929,"gmtCreate":1623859344761,"gmtModify":1703821752161,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163393929","repostId":"2143535759","repostType":2,"repost":{"id":"2143535759","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623757576,"share":"https://ttm.financial/m/news/2143535759?lang=en_US&edition=fundamental","pubTime":"2021-06-15 19:46","market":"us","language":"en","title":"Novavax's COVID-19 vaccine to be made in India soon - govt official","url":"https://stock-news.laohu8.com/highlight/detail?id=2143535759","media":"Reuters","summary":"BENGALURU, June 15 (Reuters) - The Serum Institute of India is preparing to produce Novavax's COV","content":"<html><body><p>BENGALURU, June 15 (Reuters) - The Serum Institute of India is preparing to produce Novavax's COVID-19 vaccine in the country, government official Vinod Kumar Paul said at a press briefing on Tuesday.</p><p> The vaccine maker on Monday had said its COVID-19 vaccine was more than 90% effective in a large, late-stage U.S.-based clinical trial. </p><p> (Reporting by Shivani Singh in Bengaluru, editing by Louise Heavens)</p><p>((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax's COVID-19 vaccine to be made in India soon - govt official</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax's COVID-19 vaccine to be made in India soon - govt official\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-15 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>BENGALURU, June 15 (Reuters) - The Serum Institute of India is preparing to produce Novavax's COVID-19 vaccine in the country, government official Vinod Kumar Paul said at a press briefing on Tuesday.</p><p> The vaccine maker on Monday had said its COVID-19 vaccine was more than 90% effective in a large, late-stage U.S.-based clinical trial. </p><p> (Reporting by Shivani Singh in Bengaluru, editing by Louise Heavens)</p><p>((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143535759","content_text":"BENGALURU, June 15 (Reuters) - The Serum Institute of India is preparing to produce Novavax's COVID-19 vaccine in the country, government official Vinod Kumar Paul said at a press briefing on Tuesday. The vaccine maker on Monday had said its COVID-19 vaccine was more than 90% effective in a large, late-stage U.S.-based clinical trial. (Reporting by Shivani Singh in Bengaluru, editing by Louise Heavens)((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163399113,"gmtCreate":1623859323232,"gmtModify":1703821751029,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163399113","repostId":"1107989851","repostType":2,"repost":{"id":"1107989851","kind":"news","pubTimestamp":1623833866,"share":"https://ttm.financial/m/news/1107989851?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:57","market":"us","language":"en","title":"Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=1107989851","media":"benzinga","summary":"Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as Septemb","content":"<div>\n<p>Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax COVID-19 Vaccine Could Become Available In India By September, Says Partner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:57 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107989851","content_text":"Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage of completion in India following which the U.S.-based vaccine maker’s India partner Serum Institute of India (SII) will launch the vaccine, the report said citing Adar Poonawalla, chief executive officer at SII.\nNovavax’s coronavirus vaccine trial in India is likely to conclude by November, however, the pharma company can apply for a license for the vaccine on the basis of global data, Poonawalla noted.\nThe U.S.-based biotechnology firm had earlier this week said that its COVID-19vaccine demonstratedover 90.4% efficacy. The study enrolled 29,960 participants.\nNovavax is also planning to start clinical trials of Covovax for children in July, the report added. Novavax and SII had in September partnered for the former's COVID-19 vaccine candidate NVX-CoV2373.\nAstraZeneca Inc's vaccine, marketed as \"Covishied\" in the country, is currently being widely administered as part of the vaccination drive in India, alongside locally produced Covaxin and Russia's Sputnik V.\nOcugen Inc. is the U.S. partner for Covaxin.\nPrice Action:Novavax shares closed 9.94% at $187.07 on Tuesday and were down 0.68% in extended hours.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1728,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163912764,"gmtCreate":1623856436058,"gmtModify":1703821643430,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163912764","repostId":"1107989851","repostType":2,"repost":{"id":"1107989851","kind":"news","pubTimestamp":1623833866,"share":"https://ttm.financial/m/news/1107989851?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:57","market":"us","language":"en","title":"Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=1107989851","media":"benzinga","summary":"Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as Septemb","content":"<div>\n<p>Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax COVID-19 Vaccine Could Become Available In India By September, Says Partner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:57 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107989851","content_text":"Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage of completion in India following which the U.S.-based vaccine maker’s India partner Serum Institute of India (SII) will launch the vaccine, the report said citing Adar Poonawalla, chief executive officer at SII.\nNovavax’s coronavirus vaccine trial in India is likely to conclude by November, however, the pharma company can apply for a license for the vaccine on the basis of global data, Poonawalla noted.\nThe U.S.-based biotechnology firm had earlier this week said that its COVID-19vaccine demonstratedover 90.4% efficacy. The study enrolled 29,960 participants.\nNovavax is also planning to start clinical trials of Covovax for children in July, the report added. Novavax and SII had in September partnered for the former's COVID-19 vaccine candidate NVX-CoV2373.\nAstraZeneca Inc's vaccine, marketed as \"Covishied\" in the country, is currently being widely administered as part of the vaccination drive in India, alongside locally produced Covaxin and Russia's Sputnik V.\nOcugen Inc. is the U.S. partner for Covaxin.\nPrice Action:Novavax shares closed 9.94% at $187.07 on Tuesday and were down 0.68% in extended hours.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1892,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163992751,"gmtCreate":1623855636473,"gmtModify":1703821614770,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163992751","repostId":"1107989851","repostType":2,"repost":{"id":"1107989851","kind":"news","pubTimestamp":1623833866,"share":"https://ttm.financial/m/news/1107989851?lang=en_US&edition=fundamental","pubTime":"2021-06-16 16:57","market":"us","language":"en","title":"Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=1107989851","media":"benzinga","summary":"Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as Septemb","content":"<div>\n<p>Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax COVID-19 Vaccine Could Become Available In India By September, Says Partner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:57 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.benzinga.com/general/biotech/21/06/21581892/novavax-covid-19-vaccine-could-become-available-in-india-by-september-says-partner","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107989851","content_text":"Novavax Inc COVID-19 vaccine, marketed as \"Covovax,\" could see a launch in India as early as September, Moneycontrol reportedon Wednesday.\nWhat Happened:Covovax trials have reached an advanced stage of completion in India following which the U.S.-based vaccine maker’s India partner Serum Institute of India (SII) will launch the vaccine, the report said citing Adar Poonawalla, chief executive officer at SII.\nNovavax’s coronavirus vaccine trial in India is likely to conclude by November, however, the pharma company can apply for a license for the vaccine on the basis of global data, Poonawalla noted.\nThe U.S.-based biotechnology firm had earlier this week said that its COVID-19vaccine demonstratedover 90.4% efficacy. The study enrolled 29,960 participants.\nNovavax is also planning to start clinical trials of Covovax for children in July, the report added. Novavax and SII had in September partnered for the former's COVID-19 vaccine candidate NVX-CoV2373.\nAstraZeneca Inc's vaccine, marketed as \"Covishied\" in the country, is currently being widely administered as part of the vaccination drive in India, alongside locally produced Covaxin and Russia's Sputnik V.\nOcugen Inc. is the U.S. partner for Covaxin.\nPrice Action:Novavax shares closed 9.94% at $187.07 on Tuesday and were down 0.68% in extended hours.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169506018,"gmtCreate":1623841217534,"gmtModify":1703821039250,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169506018","repostId":"1185142374","repostType":4,"repost":{"id":"1185142374","kind":"news","pubTimestamp":1623811255,"share":"https://ttm.financial/m/news/1185142374?lang=en_US&edition=fundamental","pubTime":"2021-06-16 10:40","market":"us","language":"en","title":"The Fed Should Talk About Tapering. Here’s What Could Happen to the Stock Market.","url":"https://stock-news.laohu8.com/highlight/detail?id=1185142374","media":"Barrons","summary":"Investors expect the Federal Reserve to remain supportive of the economy and financial markets. But ","content":"<p>Investors expect the Federal Reserve to remain supportive of the economy and financial markets. But the central bank has limited margin for error, and any miscues on messaging could be costly to the stock market.</p>\n<p>Markets do not expect the Fed to make any sudden or drastic changes to its current easy-money policy. The 10-year Treasury bond’s yield has fallen to 1.51% from 1.64% a month ago, even as inflation has run hotter than expected. The Nasdaq 100, an index of large capitalization and fast-growing technology companies,is up more than 5% in the past month. Growth stocks see a significant valuation booster when long-dated bond yields remain low, as growth companies expect growing profits on a particularly long-term basis. But while investors expect the Fed to soon reduce the size of its bond-buying program, which would raise bond prices and lower their yields, most don’t think the Fed will do so immediately or drastically.</p>\n<p>“It’s pretty clear that the market expects Fed Chair Powell to strongly reiterate his stances,” writes Chris Senyek, chief investment strategist at Wolfe Research.</p>\n<p>Now, the Fed could stoke a harsh move downwards in tech stocks if it doesn’t choose its words wisely. With the Nasdaq 100 hovering just below a new all-time high set on June 14—accompanied with a 10-year Treasury bond yield that’s well below its 2021 peak of 1.75%—tech stocks are vulnerable to a downward jolt if the Fed misspeaks. Senyek notes that the Fed may indeed be more ready to taper—or reduce the size of its bond-buying program—than some appreciate. He cites the recently hot inflation. To be sure, most market participants see inflation as transitory, a result of a natural year-over-year bounce from low prices during last year’s lockdown. Even so, if the Fed speaks in a way that indicates it will begin tapering before the end of the year—which is the expected timing—stocks could fall sharply.</p>\n<p>“With both stocks and bonds currently ‘priced for perfection,’ the slightest miscommunication could spark a sharp selloff,” says Senyek, who cites the Nasdsaq 100’s recent rise.</p>\n<p>Watch to see if the Fed is about to begin tapering, or is merely considering the move in the coming quarters.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Fed Should Talk About Tapering. Here’s What Could Happen to the Stock Market.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Fed Should Talk About Tapering. Here’s What Could Happen to the Stock Market.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 10:40 GMT+8 <a href=https://www.barrons.com/articles/the-fed-tapering-stock-market-51623777984?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors expect the Federal Reserve to remain supportive of the economy and financial markets. But the central bank has limited margin for error, and any miscues on messaging could be costly to the ...</p>\n\n<a href=\"https://www.barrons.com/articles/the-fed-tapering-stock-market-51623777984?mod=RTA\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/the-fed-tapering-stock-market-51623777984?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185142374","content_text":"Investors expect the Federal Reserve to remain supportive of the economy and financial markets. But the central bank has limited margin for error, and any miscues on messaging could be costly to the stock market.\nMarkets do not expect the Fed to make any sudden or drastic changes to its current easy-money policy. The 10-year Treasury bond’s yield has fallen to 1.51% from 1.64% a month ago, even as inflation has run hotter than expected. The Nasdaq 100, an index of large capitalization and fast-growing technology companies,is up more than 5% in the past month. Growth stocks see a significant valuation booster when long-dated bond yields remain low, as growth companies expect growing profits on a particularly long-term basis. But while investors expect the Fed to soon reduce the size of its bond-buying program, which would raise bond prices and lower their yields, most don’t think the Fed will do so immediately or drastically.\n“It’s pretty clear that the market expects Fed Chair Powell to strongly reiterate his stances,” writes Chris Senyek, chief investment strategist at Wolfe Research.\nNow, the Fed could stoke a harsh move downwards in tech stocks if it doesn’t choose its words wisely. With the Nasdaq 100 hovering just below a new all-time high set on June 14—accompanied with a 10-year Treasury bond yield that’s well below its 2021 peak of 1.75%—tech stocks are vulnerable to a downward jolt if the Fed misspeaks. Senyek notes that the Fed may indeed be more ready to taper—or reduce the size of its bond-buying program—than some appreciate. He cites the recently hot inflation. To be sure, most market participants see inflation as transitory, a result of a natural year-over-year bounce from low prices during last year’s lockdown. Even so, if the Fed speaks in a way that indicates it will begin tapering before the end of the year—which is the expected timing—stocks could fall sharply.\n“With both stocks and bonds currently ‘priced for perfection,’ the slightest miscommunication could spark a sharp selloff,” says Senyek, who cites the Nasdsaq 100’s recent rise.\nWatch to see if the Fed is about to begin tapering, or is merely considering the move in the coming quarters.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160344358,"gmtCreate":1623773556474,"gmtModify":1703819097845,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160344358","repostId":"2143529457","repostType":2,"isVote":1,"tweetType":1,"viewCount":2019,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187137516,"gmtCreate":1623746033335,"gmtModify":1704210208692,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187137516","repostId":"1123375053","repostType":4,"isVote":1,"tweetType":1,"viewCount":1568,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185625210,"gmtCreate":1623647233530,"gmtModify":1704207781567,"author":{"id":"3573863031138354","authorId":"3573863031138354","name":"optoons65","avatar":"https://static.tigerbbs.com/aaeba405066fd52abd26037f04ff463c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573863031138354","idStr":"3573863031138354"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/185625210","repostId":"1108979879","repostType":2,"repost":{"id":"1108979879","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623163019,"share":"https://ttm.financial/m/news/1108979879?lang=en_US&edition=fundamental","pubTime":"2021-06-08 22:36","market":"us","language":"en","title":"EV stocks rose in morning trading, as sales strong","url":"https://stock-news.laohu8.com/highlight/detail?id=1108979879","media":"Tiger Newspress","summary":"EV stocks rose in morning trading, as sales strong. Li surged 8%. Li Auto reported May deliveries of","content":"<p>EV stocks rose in morning trading, as sales strong. Li surged 8%. <b>Li Auto</b> reported May deliveries of 4,323, up 101% from the same period last year, but down 22% from April.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c15df0bb7dbeed4971538b0d23829b59\" tg-width=\"323\" tg-height=\"283\" referrerpolicy=\"no-referrer\"><span>10:36 am ET</span></p><p><b>Tesla</b> sales in China rebounded in May, amid growing government scrutiny and global chip and battery shortages. Tesla stock rose Tuesday.</p><p>China Passenger Car Association data shows Tesla sold 33,463 EVs in May, up 29.5% from 25,845 in April. Tesla sales were 35,478 in March.</p><p>Tesla China wholesale sales were 33,463 in May, including 21,936 in domestic sales and 11,527 for export. That's according to the China Passenger Car Association.</p><p>In May, Tesla exported 11,527 vehicles from China. Tesla's local sales surged 88% vs. April to 21,936.</p><p>April's shipments declined 27% from March, but excluding 14,174 vehicles that were shipped to Europe, domestic sales was actually 67% month over month. Prior reports excluded Tesla exports.</p><p>The May sales rebound in China follows weeks of state media coverage regarding customer complaints and increased government oversight. Last week, a report said that Tesla orders nearly halved in May. But Tesla orders from last month may not be filled until this summer.</p><p>\"Tesla appears to have handled the shaky China PR issues and turbulence well as demand rebounded well ahead of expectations,\" said Wedbush analyst Daniel Ives in a note to clients Tuesday.</p><p><b>China EV Sales Strong</b></p><p>Meanwhile, Tesla's China-based rivals reportedstrong May saleslast week. <b>Nio</b>(NIO) deliveries rose 95% to 6,711 electric SUVs in May. But month-over-month deliveries fell about 6%.</p><p><b>Xpeng</b>(XPEV) deliveries leapt 483% year over year to 5,686 EVs in May, and 10% from April. <b>Li Auto</b>(LI) reported May deliveries of 4,323, up 101% from the same period last year, but down 22% from April.</p><p>China's new electric vehicle sales, which include EVs, hybrids and fuel cell vehicles, surged 177% to 185,000 cars in May from a year earlier, CPCA said. EV sales alone leapt 186% to 162,000.</p><p>Overall passenger vehicle sales, however, rose just 1.1% to 1.66 million cars.</p><p>Despite a recent rough patch that includes Autopilot safety concerns and the chip shortage, Ives is confident in Tesla's long-term ability to lead in the region.</p><p>\"Only 5% of auto sales in China are EV driven today, and we believe this transformational consumer demand will see a doubling of EV deliveries in this key region over the next two years with Tesla a major beneficiary along with domestic pure plays NIO, Xpeng, Li Auto and others,\" he said.</p><p>Ives has an outperform rating on Tesla stock and a price target of 1,000.</p><p><b>Tesla Stock</b></p><p>Shares rose 0.9% to 610.66 on thestock market today. Tesla stock has regained support at the 200-day line. It is still below its 50-day line,MarketSmithchart analysis shows. Its relative strength lineis rebounding.</p><p>Nio stock advanced 1.4% Tuesday. Xpeng stock rose 4and Li Auto climbed 8.3%.</p><p>China accounts for 30% of Tesla's sales. It is the second-largest market for the EV maker, behind the U.S.</p><p>Beijing officials warmly welcomed Tesla early on, as it facilitated the opening of its Giga Shanghai plant in 2019. But recent consumer complaints about Tesla vehicle safety and the company's response to criticisms have irked Chinese officials. The strained relationship has resulted in bad PR for the U.S.-based electric carmaker.</p><p>Global chip and battery shortages have also stymied Tesla's growth plans. Most recently, the companyscrapped plans to make a Plaid Plusversion of its luxury Model S vehicle. While CEO Elon Musk tweeted the decision was made because the Plaid was \"good enough,\" some industry observers have said the reversal could be due to battery supply issues.</p><p>The Plaid Plus, along with the Cybertruck, Tesla Semi and some future Model Y vehicles, were all slated to use 4680 battery cells, which are supposed to offer a big advance in range and cost. But Tesla has said mass production of the 4680 battery cells may not occur until well into 2022.</p><p>Meanwhile, long-term executive Jerome Guillen has stepped down, Tesla announced late Monday. Guillen, who helped launch the Model 3 and Model Y, had transitioned to head up the Tesla Semi development in March.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks rose in morning trading, as sales strong</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks rose in morning trading, as sales strong\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-08 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks rose in morning trading, as sales strong. Li surged 8%. <b>Li Auto</b> reported May deliveries of 4,323, up 101% from the same period last year, but down 22% from April.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c15df0bb7dbeed4971538b0d23829b59\" tg-width=\"323\" tg-height=\"283\" referrerpolicy=\"no-referrer\"><span>10:36 am ET</span></p><p><b>Tesla</b> sales in China rebounded in May, amid growing government scrutiny and global chip and battery shortages. Tesla stock rose Tuesday.</p><p>China Passenger Car Association data shows Tesla sold 33,463 EVs in May, up 29.5% from 25,845 in April. Tesla sales were 35,478 in March.</p><p>Tesla China wholesale sales were 33,463 in May, including 21,936 in domestic sales and 11,527 for export. That's according to the China Passenger Car Association.</p><p>In May, Tesla exported 11,527 vehicles from China. Tesla's local sales surged 88% vs. April to 21,936.</p><p>April's shipments declined 27% from March, but excluding 14,174 vehicles that were shipped to Europe, domestic sales was actually 67% month over month. Prior reports excluded Tesla exports.</p><p>The May sales rebound in China follows weeks of state media coverage regarding customer complaints and increased government oversight. Last week, a report said that Tesla orders nearly halved in May. But Tesla orders from last month may not be filled until this summer.</p><p>\"Tesla appears to have handled the shaky China PR issues and turbulence well as demand rebounded well ahead of expectations,\" said Wedbush analyst Daniel Ives in a note to clients Tuesday.</p><p><b>China EV Sales Strong</b></p><p>Meanwhile, Tesla's China-based rivals reportedstrong May saleslast week. <b>Nio</b>(NIO) deliveries rose 95% to 6,711 electric SUVs in May. But month-over-month deliveries fell about 6%.</p><p><b>Xpeng</b>(XPEV) deliveries leapt 483% year over year to 5,686 EVs in May, and 10% from April. <b>Li Auto</b>(LI) reported May deliveries of 4,323, up 101% from the same period last year, but down 22% from April.</p><p>China's new electric vehicle sales, which include EVs, hybrids and fuel cell vehicles, surged 177% to 185,000 cars in May from a year earlier, CPCA said. EV sales alone leapt 186% to 162,000.</p><p>Overall passenger vehicle sales, however, rose just 1.1% to 1.66 million cars.</p><p>Despite a recent rough patch that includes Autopilot safety concerns and the chip shortage, Ives is confident in Tesla's long-term ability to lead in the region.</p><p>\"Only 5% of auto sales in China are EV driven today, and we believe this transformational consumer demand will see a doubling of EV deliveries in this key region over the next two years with Tesla a major beneficiary along with domestic pure plays NIO, Xpeng, Li Auto and others,\" he said.</p><p>Ives has an outperform rating on Tesla stock and a price target of 1,000.</p><p><b>Tesla Stock</b></p><p>Shares rose 0.9% to 610.66 on thestock market today. Tesla stock has regained support at the 200-day line. It is still below its 50-day line,MarketSmithchart analysis shows. Its relative strength lineis rebounding.</p><p>Nio stock advanced 1.4% Tuesday. Xpeng stock rose 4and Li Auto climbed 8.3%.</p><p>China accounts for 30% of Tesla's sales. It is the second-largest market for the EV maker, behind the U.S.</p><p>Beijing officials warmly welcomed Tesla early on, as it facilitated the opening of its Giga Shanghai plant in 2019. But recent consumer complaints about Tesla vehicle safety and the company's response to criticisms have irked Chinese officials. The strained relationship has resulted in bad PR for the U.S.-based electric carmaker.</p><p>Global chip and battery shortages have also stymied Tesla's growth plans. Most recently, the companyscrapped plans to make a Plaid Plusversion of its luxury Model S vehicle. While CEO Elon Musk tweeted the decision was made because the Plaid was \"good enough,\" some industry observers have said the reversal could be due to battery supply issues.</p><p>The Plaid Plus, along with the Cybertruck, Tesla Semi and some future Model Y vehicles, were all slated to use 4680 battery cells, which are supposed to offer a big advance in range and cost. But Tesla has said mass production of the 4680 battery cells may not occur until well into 2022.</p><p>Meanwhile, long-term executive Jerome Guillen has stepped down, Tesla announced late Monday. Guillen, who helped launch the Model 3 and Model Y, had transitioned to head up the Tesla Semi development in March.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","NIO":"蔚来","TSLA":"特斯拉","LI":"理想汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108979879","content_text":"EV stocks rose in morning trading, as sales strong. Li surged 8%. Li Auto reported May deliveries of 4,323, up 101% from the same period last year, but down 22% from April.10:36 am ETTesla sales in China rebounded in May, amid growing government scrutiny and global chip and battery shortages. Tesla stock rose Tuesday.China Passenger Car Association data shows Tesla sold 33,463 EVs in May, up 29.5% from 25,845 in April. Tesla sales were 35,478 in March.Tesla China wholesale sales were 33,463 in May, including 21,936 in domestic sales and 11,527 for export. That's according to the China Passenger Car Association.In May, Tesla exported 11,527 vehicles from China. Tesla's local sales surged 88% vs. April to 21,936.April's shipments declined 27% from March, but excluding 14,174 vehicles that were shipped to Europe, domestic sales was actually 67% month over month. Prior reports excluded Tesla exports.The May sales rebound in China follows weeks of state media coverage regarding customer complaints and increased government oversight. Last week, a report said that Tesla orders nearly halved in May. But Tesla orders from last month may not be filled until this summer.\"Tesla appears to have handled the shaky China PR issues and turbulence well as demand rebounded well ahead of expectations,\" said Wedbush analyst Daniel Ives in a note to clients Tuesday.China EV Sales StrongMeanwhile, Tesla's China-based rivals reportedstrong May saleslast week. Nio(NIO) deliveries rose 95% to 6,711 electric SUVs in May. But month-over-month deliveries fell about 6%.Xpeng(XPEV) deliveries leapt 483% year over year to 5,686 EVs in May, and 10% from April. Li Auto(LI) reported May deliveries of 4,323, up 101% from the same period last year, but down 22% from April.China's new electric vehicle sales, which include EVs, hybrids and fuel cell vehicles, surged 177% to 185,000 cars in May from a year earlier, CPCA said. EV sales alone leapt 186% to 162,000.Overall passenger vehicle sales, however, rose just 1.1% to 1.66 million cars.Despite a recent rough patch that includes Autopilot safety concerns and the chip shortage, Ives is confident in Tesla's long-term ability to lead in the region.\"Only 5% of auto sales in China are EV driven today, and we believe this transformational consumer demand will see a doubling of EV deliveries in this key region over the next two years with Tesla a major beneficiary along with domestic pure plays NIO, Xpeng, Li Auto and others,\" he said.Ives has an outperform rating on Tesla stock and a price target of 1,000.Tesla StockShares rose 0.9% to 610.66 on thestock market today. Tesla stock has regained support at the 200-day line. It is still below its 50-day line,MarketSmithchart analysis shows. Its relative strength lineis rebounding.Nio stock advanced 1.4% Tuesday. Xpeng stock rose 4and Li Auto climbed 8.3%.China accounts for 30% of Tesla's sales. It is the second-largest market for the EV maker, behind the U.S.Beijing officials warmly welcomed Tesla early on, as it facilitated the opening of its Giga Shanghai plant in 2019. But recent consumer complaints about Tesla vehicle safety and the company's response to criticisms have irked Chinese officials. The strained relationship has resulted in bad PR for the U.S.-based electric carmaker.Global chip and battery shortages have also stymied Tesla's growth plans. Most recently, the companyscrapped plans to make a Plaid Plusversion of its luxury Model S vehicle. While CEO Elon Musk tweeted the decision was made because the Plaid was \"good enough,\" some industry observers have said the reversal could be due to battery supply issues.The Plaid Plus, along with the Cybertruck, Tesla Semi and some future Model Y vehicles, were all slated to use 4680 battery cells, which are supposed to offer a big advance in range and cost. But Tesla has said mass production of the 4680 battery cells may not occur until well into 2022.Meanwhile, long-term executive Jerome Guillen has stepped down, Tesla announced late Monday. Guillen, who helped launch the Model 3 and Model Y, had transitioned to head up the Tesla Semi development in March.","news_type":1,"symbols_score_info":{"LI":0.9,"NIO":0.9,"TSLA":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":2366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}